FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980357787> ?p ?o ?g. }

• W2980357787 endingPage "121" @default.
• W2980357787 startingPage "107" @default.
• W2980357787 abstract "Background: Certain governmental agencies, patient advocacy organizations, and pharmaceutical manufacturers have implemented programs to assist patients in overcoming barriers to accessing healthcare. Recently, such programs have expanded their services, helping both uninsured and insured patients to navigate the complex healthcare system, and assisting with increasing out-of pocket costs and copays for the drugs. Objective: To better understand the effect of patient support programs on access to therapy for solid tumor malignancies, this study evaluated service use, case outcomes, and patient characteristics from a manufacturer-sponsored program in the United States. Methods: Sociodemographic characteristics, services use rates, and outcomes by case and insurance type were evaluated at the patient- and case-level in a random sample of patients prescribed nab-paclitaxel for solid tumor malignancies who enrolled in the Celgene Patient Support (CPS) program (April 2011–November 2013). Results: This analysis included 4566 patients (8134 cases); most patients were female (64.7%), aged &lt;65 years (59.2%), in the South (53.9%), and treated in community settings (87.9%). Patients were primarily insured by Medicare (38.5%) or commercial plans (37.3%), or were uninsured (16.6%). Following benefits investigations for new patients entering the program (98.5%), CPS provided support to obtain free medicine (29.4%), appeal denial of coverage (15.0%), receive commercial co-payment assistance (8.1%), or obtain prior payer authorization (1.3%). Nab-paclitaxel was provided at no cost in 89.4% of cases where patients sought financial support; payer reimbursement was obtained in 63.2% of reimbursement appeals. Of commercially-insured patients who required assistance with co-payments and met financial criteria, 93.3% received a mean of $597 in co-payment support. Conclusion: The CPS program was successful in gaining access to therapy. Healthcare providers and both insured or uninsured patients accessed CPS for prior authorization/precertification, appeals support, and financial support through the Free Medication Program and the Commercial Co-Pay program." @default.
• W2980357787 created "2019-10-25" @default.
• W2980357787 creator A5045235561 @default.
• W2980357787 creator A5062733502 @default.
• W2980357787 creator A5067898579 @default.
• W2980357787 creator A5075283013 @default.
• W2980357787 date "2016-10-27" @default.
• W2980357787 modified "2023-10-18" @default.
• W2980357787 title "Effectiveness of a Patient Support Program in Supporting Access to Therapy for Solid Tumor Malignancies" @default.
• W2980357787 cites W1515201294 @default.
• W2980357787 cites W1884459095 @default.
• W2980357787 cites W1969203795 @default.
• W2980357787 cites W1987397089 @default.
• W2980357787 cites W1996267272 @default.
• W2980357787 cites W1996564332 @default.
• W2980357787 cites W2011935764 @default.
• W2980357787 cites W2025833869 @default.
• W2980357787 cites W2030148250 @default.
• W2980357787 cites W2118345987 @default.
• W2980357787 cites W2134440776 @default.
• W2980357787 cites W2144526050 @default.
• W2980357787 cites W2160816097 @default.
• W2980357787 cites W2162627162 @default.
• W2980357787 cites W2169392244 @default.
• W2980357787 cites W2170915815 @default.
• W2980357787 cites W2413672945 @default.
• W2980357787 doi "https://doi.org/10.36469/9846" @default.
• W2980357787 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37662657" @default.
• W2980357787 hasPublicationYear "2016" @default.
• W2980357787 type Work @default.
• W2980357787 sameAs 2980357787 @default.
• W2980357787 citedByCount "1" @default.
• W2980357787 countsByYear W29803577872022 @default.
• W2980357787 crossrefType "journal-article" @default.
• W2980357787 hasAuthorship W2980357787A5045235561 @default.
• W2980357787 hasAuthorship W2980357787A5062733502 @default.
• W2980357787 hasAuthorship W2980357787A5067898579 @default.
• W2980357787 hasAuthorship W2980357787A5075283013 @default.
• W2980357787 hasBestOaLocation W29803577871 @default.
• W2980357787 hasConcept C10138342 @default.
• W2980357787 hasConcept C108759981 @default.
• W2980357787 hasConcept C11171543 @default.
• W2980357787 hasConcept C144133560 @default.
• W2980357787 hasConcept C145097563 @default.
• W2980357787 hasConcept C15744967 @default.
• W2980357787 hasConcept C159110408 @default.
• W2980357787 hasConcept C160735492 @default.
• W2980357787 hasConcept C162324750 @default.
• W2980357787 hasConcept C162853370 @default.
• W2980357787 hasConcept C17744445 @default.
• W2980357787 hasConcept C199539241 @default.
• W2980357787 hasConcept C2778449503 @default.
• W2980357787 hasConcept C2779598192 @default.
• W2980357787 hasConcept C2779703844 @default.
• W2980357787 hasConcept C2780378061 @default.
• W2980357787 hasConcept C2780900520 @default.
• W2980357787 hasConcept C38652104 @default.
• W2980357787 hasConcept C41008148 @default.
• W2980357787 hasConcept C50522688 @default.
• W2980357787 hasConcept C512399662 @default.
• W2980357787 hasConcept C71924100 @default.
• W2980357787 hasConceptScore W2980357787C10138342 @default.
• W2980357787 hasConceptScore W2980357787C108759981 @default.
• W2980357787 hasConceptScore W2980357787C11171543 @default.
• W2980357787 hasConceptScore W2980357787C144133560 @default.
• W2980357787 hasConceptScore W2980357787C145097563 @default.
• W2980357787 hasConceptScore W2980357787C15744967 @default.
• W2980357787 hasConceptScore W2980357787C159110408 @default.
• W2980357787 hasConceptScore W2980357787C160735492 @default.
• W2980357787 hasConceptScore W2980357787C162324750 @default.
• W2980357787 hasConceptScore W2980357787C162853370 @default.
• W2980357787 hasConceptScore W2980357787C17744445 @default.
• W2980357787 hasConceptScore W2980357787C199539241 @default.
• W2980357787 hasConceptScore W2980357787C2778449503 @default.
• W2980357787 hasConceptScore W2980357787C2779598192 @default.
• W2980357787 hasConceptScore W2980357787C2779703844 @default.
• W2980357787 hasConceptScore W2980357787C2780378061 @default.
• W2980357787 hasConceptScore W2980357787C2780900520 @default.
• W2980357787 hasConceptScore W2980357787C38652104 @default.
• W2980357787 hasConceptScore W2980357787C41008148 @default.
• W2980357787 hasConceptScore W2980357787C50522688 @default.
• W2980357787 hasConceptScore W2980357787C512399662 @default.
• W2980357787 hasConceptScore W2980357787C71924100 @default.
• W2980357787 hasIssue "1" @default.
• W2980357787 hasLocation W29803577871 @default.
• W2980357787 hasLocation W29803577872 @default.
• W2980357787 hasOpenAccess W2980357787 @default.
• W2980357787 hasPrimaryLocation W29803577871 @default.
• W2980357787 hasRelatedWork W1983808260 @default.
• W2980357787 hasRelatedWork W2063544597 @default.
• W2980357787 hasRelatedWork W2106854734 @default.
• W2980357787 hasRelatedWork W2155761001 @default.
• W2980357787 hasRelatedWork W2411046411 @default.
• W2980357787 hasRelatedWork W2462529827 @default.
• W2980357787 hasRelatedWork W3113172828 @default.
• W2980357787 hasRelatedWork W3199009715 @default.
• W2980357787 hasRelatedWork W4220703427 @default.
• W2980357787 hasRelatedWork W4297926687 @default.

• next